Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market
Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market
Fierce Pharma
Herceptin
Avastin
Roche
biosimilars
Allergan
Amgen
Flag link:
Upcoming events – catalysts approach for Catalyst and Oxurion
Upcoming events – catalysts approach for Catalyst and Oxurion
EP Vantage
Catalyst Bioscences
Oxurion
Firdapse
ThromboGenics
THR-149
Flag link:
Acasti sits pretty as raise brings $400M for Amarin
Acasti sits pretty as raise brings $400M for Amarin
BioWorld
Amarin
Vascepa
FDA
Acasti
Flag link:
Does Precision Medicine Have A Minority Problem?
Does Precision Medicine Have A Minority Problem?
Forbes
precision medicine
personalized medicine
racial discrimination
minorties
Flag link:
An EKG for the Knee
An EKG for the Knee
Medical Devices and Diagnostics Industry
diagnostics
devices
KneeKG
knee injury
osteoarthritis of the knee
Emovi
Flag link:
July 19 2019 - How Pfizer oncology is juggling 8 US launches
Flag link:
Pfizer's keys to juggling 8 U.S. launches? Organization, accountability, clear goals
Pfizer's keys to juggling 8 U.S. launches? Organization, accountability, clear goals
Fierce Pharma
Pfizer
oncology
drug launches
biosimilars
Flag link:
Did cancer clinical trials stay on track at ASCO 2019?
Did cancer clinical trials stay on track at ASCO 2019?
Pharmaforum
ASCO
clinical trials
cancer
ASCO 2019
bladder cancer
breast cancer
prostate cancer
pancreatic cancer
Flag link:
Here's Why Pacific Biosciences Is Tumbling Today
Here's Why Pacific Biosciences Is Tumbling Today
Motley Fool
Pacific Biosciences
Europe
patents
DNA sequencing
Flag link:
Ultragenyx close to learning whether gene therapy gamble will pay off
Ultragenyx close to learning whether gene therapy gamble will pay off
Biopharma Dive
Ultragenyx
Dimension Therapeutics
gene therapy
DTX-301
DTX-401
Flag link:
NASH-linked gene discovery could inspire new drugs to treat liver damage
NASH-linked gene discovery could inspire new drugs to treat liver damage
Fierce Biotech
NASH
R&D
drug development
genetics
liver damage
liver fibrosis
Flag link:
Novartis licenses out early antiviral work to Gilead
Novartis licenses out early antiviral work to Gilead
Fierce Biotech
Gilead Sciences
Novartis
antivirals
Flag link:
Precision BioSciences backs off-the-shelf cancer cell therapy effort with new manufacturing plant
Precision BioSciences backs off-the-shelf cancer cell therapy effort with new manufacturing plant
Endpoints
Precision Biosciences
cell therapy
CAR-T
drug manufacturing
Flag link:
Novel drug approvals head for a down year
Novel drug approvals head for a down year
EP Vantage
FDA
drug approvals
novel drugs
Flag link:
Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts
Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts
Fierce Pharma
Novartis
generics
Sandoz
Flag link:
Roche and Novo Nordisk Top Clinical Trial Transparency Survey
Roche and Novo Nordisk Top Clinical Trial Transparency Survey
BioSpace
Roche
Novo Nordisk
JNJ
clinical trials
clinical trial transparency
Flag link:
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
Investors Business Daily
Bristol-Myers Squibb
Celgene
M&A
Otezla
Gilead Sciences
Amgen
Regeneron
Eli Lilly
JNJ
Flag link:
Do Elon Musk’s brain-decoding implants have potential? Experts say they just might
Do Elon Musk’s brain-decoding implants have potential? Experts say they just might
Stat
Elon Musk
artificial intelligence
Neuralink
brain implants
Flag link:
As for Abbott's Libre, 'You Ain't Seen Nothin' Yet'
As for Abbott's Libre, 'You Ain't Seen Nothin' Yet'
Medical Devices and Diagnostics Industry
Abbott Labs
Miles White
devices
FreeStyle Libre
blood glucose monitoring
diabetes
Flag link:
Payers, patients coming on board for Novartis’ Zolgensma
Payers, patients coming on board for Novartis’ Zolgensma
BioCentury
Novartis
Zolgensma
SMA
gene therapy
payers
patients
Flag link:

Pages